INTRODUCTION {#sec1}
============

Addiction is currently considered a primary chronic disease of brain reward, motivation, memory and related circuitry ([@ref3]). As shown in a study of [@ref84a] in patients residing in an inpatient substance treatment unit and non-alcoholics in a general medical setting, individuals with an alcohol use disorder (AUD) function more poorly than those without an AUD. Moreover, they report more negative life events and experience more chronic stressors compared to non-problem drinking individuals of elderly age ([@ref7]). Those with an AUD tend to engage less in non-drinking activities such as sport and hobbies ([@ref55]) when compared to healthy controls. In general, problematic substance use is associated with a low density of multiple types of substance-free reinforcement (Van [@ref22]; [@ref72]).

The promotion of alternative pleasant activity engagement has become increasingly clinically important as part of behavioral addiction treatment ([@ref54]; [@ref60]; [@ref38]). Understanding individual differences in behavioral and affective responses to healthy activity engagement, as a source of alternative reinforcement to compete with problematic alcohol use, is essential for the development of novel interventions (e.g. [@ref68]). From a Behavioral Choice Theory perspective ([@ref83], [@ref84]), the reinforcing valence of substances is a contextually determined product of the direct reinforcing effects of the drug, individual factors such as maladaptive impulsivity (e.g. delay discounting), sensitivity to rewards, and the availability of alternative competing reinforcers ([@ref6]). From a theoretical point of view and research conducted in pre-clinical ([@ref79]), non-clinical ([@ref15]) and clinical samples ([@ref22]; [@ref72]), a pleasant non-substance-related activity increase is negatively associated with substance use.

Multiple personality traits, such as extraversion ([@ref23]), sensation-seeking ([@ref88]) and functional impulsivity, which is defined as the tendency to act with relatively little forethought when such a style is optimal and beneficial ([@ref20]), may predispose individuals to activity engagement through a reinforcement sensitivity mechanism ([@ref77]). For example, extraversion (i.e. the tendency to be sociable, assertive, seek excitement and experience positive affect) proved to be the most prominent predictor of (physical) activity engagement ([@ref68]; [@ref73]). Extraversion reflects the 'approach' component of a dual model of personality that divides motivation and behavior into two types of action tendencies: approach and avoidance ([@ref9]). Two basic neurobehavioral systems have been described to control the approach and withdrawal tendencies: the behavioral activation system (BAS) and the BIS ([@ref32], [@ref32]; [@ref9]; [@ref27]). The BIS is activated by punishment, omission/termination of reward and novelty ([@ref33]), whereby individuals with a high BIS sensitivity tend to be sensitive to cues linked to punishment, and they inhibit behavior that leads to negative outcomes ([@ref10]). Conversely, a study investigating undergraduate students showed that individuals with a high BAS sensitivity tend to be more sensitive to cues associated with reward and tend to engage more in goal-directed behavior ([@ref10]). However, the value of BAS for understanding health-related behaviors, such as the promotion of prosocial activity engagement, in the treatment of AUD, has been relatively understudied. Nevertheless, it has been documented that BAS is positively linked with facets of pleasant activity engagement in patients with various substance use disorders ([@ref81]). Since reward sensitivity is linked with the mesolimbic dopaminergic circuits under young adult heavy drinkers in the general population ([@ref43]), and dopamine with positive affect and approach behavior ([@ref4]), reward sensitive individuals may have less efficient inhibitory dopaminergic synapses on striatal neurons associated with decreased dopamine release. Due to a lower hedonic tone, these individuals seem to be more sensitive to dopamine activation, and it makes them focus on reward cues when compared to individuals having a higher hedonic tone ([@ref17]).

Due to neurobiological adaptations of long-term substance use, the engagement in healthy activities may be affected in AUD patients, characterized by a decreased sensitivity to natural reward and increased sensitivity to compulsive alcohol and drug-seeking behavior ([@ref80]; [@ref14]). A characteristic of such a dysfunctional reward system is the systematic discounting of delayed non-substance-related rewards ([@ref44]; [@ref6]; [@ref76]), which is considered to be one of the behavioral decision-making deficits ([@ref56]). It is associated with under-engagement in healthy alternatives to drinking because of the benefits of these alternative activities are generally delayed ([@ref58]) and may not be considered as enjoyable at the moment ([@ref57]). Patients with an AUD will prefer an immediate reward over a future reward, even if the future reward has more clear advantages than an immediate reward. Discounting the value of delayed rewards (i.e. higher discount rates) is associated with impulsive choices that are focused on immediate gratification (e.g. substance-using behavior) and encumber the ability to work toward long-term goals ([@ref44]; [@ref6]; [@ref65]). Moreover, sensitivity for reward cues (i.e. BAS) predicts the behavioral decision-making deficits ([@ref26]). Individuals with high reward sensitivity tend to make more rational choices regarding smaller but more consistent gains.

Anhedonia (i.e. the inability to experience pleasure from activities usually found enjoyable; [@ref66]), is another indication of neurobiological disruptions in the dopaminergic system ([@ref36]). This complex phenomenon consists of affective, cognitive, and behavioral components ([@ref78]). Anhedonia refers both to a state symptom and to a personality trait ([@ref48]). It is shown to be a frequent symptom in patients with an AUD ([@ref37]; [@ref27]) and it plays a critical role in relapse in substance use ([@ref45]; [@ref85b]). There is a link with a dysfunction of the dopaminergic reward system as observed in pre-clinical ([@ref19]; [@ref89a]) and clinical samples ([@ref51]; [@ref37]). Moreover, it is associated with diminished reward responsivity (i.e. BAS) and reduced motivation to seek out rewarding stimuli in a non-clinical sample ([@ref30]). Furthermore, anhedonia has been negatively linked to activity engagement ([@ref47]), and to delay discounting rate in healthy individuals, suggesting that anhedonic individuals are inclined to choose a more substantial delayed reward upon a low immediate reward ([@ref46]).

The purpose of this study was to investigate the association between BAS personality trait and substance-related activities (SRAs)/non-substance-related activities (non-SRAs) in both AUD patients and healthy controls. This will contribute to a better understanding of the role of individual differences in behavioral and affective responses related to engagement in healthy activities, which is typically promoted in evidence-based addiction treatment, such as the Community Reinforcement Approach ([@ref54]). Impulsivity has been defined as 'a trait-like proclivity to engage in impulsive behaviors, either due to unusually strong impulses or to difficulty with reasoning about or controlling impulsive actions' ([@ref40], p. 3). Since it has been observed that impulsivity is positively related to delay discounting ([@ref44]) and negatively related to anhedonia ([@ref30]), the second objective of this study was to examine the differential effect of delay discounting and anhedonia on this aforementioned BAS-SRAs/non-SRAs association by performing correlational analyses. It was expected that both delay discounting and anhedonia influence the BAS-non-SRAs relationship negatively, while delay discounting and anhedonia would positively impact the BAS-SRA relationship.

Method {#sec2}
======

Participants {#sec3}
------------

After the application of the in- and exclusion criteria, the final sample in the current study consisted of 37 patients with an AUD and 37 matched healthy controls. All of these participants were included in the analyzes. The patients were diagnosed according to the guidelines of the DSM-IV ([@ref2]). Medical doctors, psychiatrists, and psychologists conducted the assessment substance use applying a clinical interview. Criteria for inclusion in the patient group were as follows: an AUD diagnosis, age between 24 and 65 years, and a minimum score of 25 on the Mini-Mental State Examination (MMSE; [@ref25]). The MMSE was employed for examination of cognitive functioning in order to increase the validity of the test instruments. As research has shown, the cut-off score of 25 points reflects adequate cognitive functioning under individuals treated in mental health centers ([@ref49]). The exclusion criteria for patients contained withdrawal symptoms. Patients that resided in the treatment center for \<7 days and had a high likelihood of experiencing withdrawal symptoms due to recent use of alcohol were not included in the present study.

Using a matched-control design (case-matched for age, gender and education level), the group of healthy controls was recruited from similar community settings (Noord-Brabant) via word-of-mouth referrals. All participants completed the Alcohol Use Disorders Identification Test (AUDIT) ([@ref74]). Since the previous research showed different optimal cut off scores of AUDIT for men and women ([@ref64]; [@ref11]; [@ref1]), separate AUDIT scores were used to identify an AUD among men and women. An AUDIT score lower than 8 (men) or 6 (woman) was required for inclusion within the control group. The non-response rate for patients was 12.2% and controls 9.2% due to time and motivational constraints. Thirteen controls were excluded from the present study because of AUDIT scores ≥ 8. No participants were excluded because of low MMSE scores. Of the total sample (*n* = 74), \>78% completed the questionnaire without any missing values. Almost 14% had one to ten missing values in the assessment battery. In total, 8% had \~20 missing values across all of the questionnaires administered.

The socio-demographic characteristics of both samples are summarized in [Table 1](#TB1){ref-type="table"}. No statistically significant differences emerged between patients and the control group with respect to the matching variables. However, statistically significant differences were found on marital status (*χ*^2^ = 34.06, *P* \< 0.001), housing (*χ*^2^ = 30.77, *P* \< 0.001), and employment (*χ*^2^ = 20.33, *P* \< 0.001). As expected, the patient group reported a higher frequency of alcohol use (*χ*^2^ = 42.44, *P* \< 0.006) and used significantly more alcohol in the past 30 days than controls \[*t* (53.39) = −11.06, *P* \< 0.001\]. More than 86% of the patients and 2.7% of the controls used alcohol at least four times a week. In total, 32% of the patients and 3% of the controls additionally used illegal drugs in the past 30 days \[*t* (36.94) = −3.52, *P* = 0.001\]. More than 13% of the patients used alcohol as well as drugs such as cannabis and cocaine (homotypic comorbidity).

###### 

Sociodemographic characteristic

                                                    Patients (*N =* 37)   Controls (*N =* 37)      Group differences
  -------------------- --------------------------- --------------------- --------------------- -------------------------
  Age (years)          47.6 (SD = 9.4)               46.5 (SD = 10.1)      *t* (82) = −0.52    
  Gender (%)           Male                                73.0                  75.7               *χ* ^2^ = 0.071
                       Female                              27.0                  24.3          
  Ethnicity (%)        European                            100.0                 100.0         
  Marital status (%)   Single                              51.4                   5.4           *χ* ^2^ = 34.06^\*\*\*^
                       Married                             18.9                  81.1          
                       Relationship                        13.5                  13.5          
                       Divorced                            10.8                   0.0          
                       Widow(er)                            5.4                   0.0          
  Housing (%)          Single                              54.1                   8.1           *χ* ^2^ = 30.76^\*\*\*^
                       With partner                        16.2                  37.8          
                       With partner and children           13.5                  54.1          
                       Single with children                 5.4                   0.0          
                       With parents                         0.0                   0.0          
                       Other                               10.8                   0.0          
  Education (%)        None                                10.8                   2.7               *χ* ^2^ = 2.16
                       Lower                               18.9                  21.6          
                       Secondary                           51.4                  59.5          
                       Higher                              18.9                  16.2          
  Employment (%)       Full-time                           35.1                  78.4           *χ* ^2^ = 20.33^\*\*\*^
                       Part-time                           18.9                  18.9          
                       Unemployed                          43.2                   2.7          
                       Other                                2.7                   0.0          

*Note*: Significant group differences indicated by ^\*^*P \<* 0*.*05; ^\*\*^*P \<* 0*.*01; ^\*\*\*^*P \<* 0*.*001.

Procedure {#sec4}
---------

All eligible participants filled in written informed consent prior to participation. After an explanation of the rationale and procedure, all patients were assessed using interviews (e.g. socio-demographic and substance use-related information) and self-reports by a team of independent researchers. During the assessment, all patients resided in an inpatient treatment center for at least 7 days (*M* = 22.77, SD = 22.87, range: 7--90) with a minimal of 7 days of abstinence (*M* = 22.19, SD = 23.64, range: 7--100). Patients' medication dosage regimen was based on a national applied protocol (De [@ref41]) by generally using chlordiazepoxide with an average dose of 40--200 mg q.i.d. or diazepam with an average dose of 20--80 mg q.i.d. As such, the dosage regime was frequently tapered within a 7-day period, based on staff observations and patients' self-reported symptoms. In general, after this period of time most of the withdrawal symptoms subsided. This study was approved by the local ethics committee (Tilburg University).

Instruments {#sec5}
-----------

### BIS/BAS Scale {#sec6}

The Behavioral Inhibition System (BIS)/BAS Scale is a self-report questionnaire that measures the individual sensitivity of the appetitive and aversive motivational system ([@ref10]). Only the BAS activation was assessed in this study by the Dutch translation of [@ref10]) BIS/BAS scales ([@ref28]). The BAS scale consists of three subscales: fun seeking (four items), reward responsiveness (five items) and drive (four items), that were merged into one BAS-scale. This because of a higher internal consistency of the newly composed BAS-scale found in previous studies ([@ref31]; [@ref61]). Moreover, the original BAS subscales strongly load on a second order BAS factor ([@ref42]; [@ref85a]; [@ref89]). All items, such as 'I go out of my way to get the things I want.', were measured on a four-point Likert scale varying from 'totally agree'(1) to 'totally disagree'(4). Higher values represent higher levels of BAS activation. Cronbach's alpha of the total BAS score in this study was 0.85.

### The Snaith--Hamilton Pleasure Scale {#sec7}

The SHAPS is a validated 14-item scale, which measures the level of anhedonia ([@ref29]). Items of the Snaith--Hamilton Pleasure Scale (SHAPS) are assessed on a five-point Likert scale varying from 'totally agree'(1) to 'totally disagree'(5). All participants rated how strongly they would enjoy various experiences that are generally considered pleasurable, for example, 'I can enjoy reading a book, magazine or newspaper.' Higher values represent higher levels of anhedonia. Cronbach's alpha of the total SHAPS score in this study was 0.91.

### Delay Discounting Task {#sec8}

A computerized Delay Discounting Task (DDT, [@ref67]) was used to study impulsive choice behavior. These impulsive choices relate to impulsive decisions resulting from a distorted evaluation of delayed behavioral consequences and an increased preference for immediate rewards over beneficial delayed rewards ([@ref8]). Participants had to answer 138 questions asking to make a choice between a smaller amount of money receiving immediately or a larger amount of the money receiving later after 7, 30, 90, 180 or 365 days. Time to choose was unlimited. For each delay period, a participant's indifference point was calculated, which reflects a point at which the participant chose a smaller immediate value instead of a larger delayed value. According to [@ref67]) delay discounting of a reward value is described by a hyperbolic discount function:

*V* = A/(1 + *k*D).

Factor V represents the indifference point, A represents the amount of the reward, the number 1 prevents the present value from approaching infinity as the delay approaches 0, and D represents the delay to the reward. The factor *k* represents a degree of discounting; it describes how steeply a value is degraded by delay ([@ref59]). It is set by the fit of the model to the data ([@ref59]). A higher discounting rate (i.e. a higher *k*-value) presents more likely a choice of an immediate smaller reward over a larger delayed reward.

### Pleasant Activities List {#sec9}

The Pleasant Activities List (PAL, [@ref72]) consists of 139 items and measures two parameters of reinforcement engagement during the previous 30 days: frequency (i.e. the amount of time engaged in the activity) and enjoyability (i.e. subjective enjoyment of the experience). Both are scored on a double five-point Likert scale varying from 'not at all'(1) to 'very often'(5). Consistent with the work of [@ref16]) an adaptation was made to distinguish between alcohol-related and non-alcohol-related events. Consequently, each item was presented twice to measure PAL SRA/non-SRA in terms of frequency and enjoyability. Since patients with AUDs frequently suffer from homotypic comorbidity (i.e. illicit drug use) as well ([@ref24]), the type of activities was expanded and rephrased to capture SRAs more generally. For example, participants rated (a) how often they go to a bar or cafe while sober and how enjoyable they experience that (non-SRA), and (b) how often they go to a bar or café while drinking alcohol or using drugs and how they enjoy this experience (SRA). The PAL SRA/non-SRA items were multiplied (frequency × enjoyability) separately for each item to calculate double cross-product scores: the PAL SRA cross-product and PAL non-SRA cross-product, as estimates of the total reported pleasure ([@ref34]). Finally, based on Herrnstein's law (1970), a reinforcement ratio (RR) was calculated that represents the proportion of reinforcement derived from PAL SRA/non-SRA cross-product relative to total reinforcement obtained over the 30-day time-window. For each participant, the PAL SRA was divided by the sum of both PAL SRA and PAL non-SRA. The PAL RR ranges from 0 to 1, with a higher ratio indicative of a greater proportion of substance-related reinforcement relative to total reinforcement. The Cronbach's alphas were between 0.96 (PAL non-SRA frequency) and 0.99 (PAL SRA cross-product).

Statistical analyses {#sec10}
--------------------

Little's chi-square statistic indicated that all missing values were missing at random (*P* \> 0.05). Missing data were replaced through Missing Value Analysis (MVA), using the Expectation Maximization (EM) imputation algorithm. The imputations were applied separately for each scale. Imputed values were generated if patients have provided valid data for \> 75% of the scale items. To normalize the *k* values (DDT), a log~10~ transformation was used. Furthermore, *t*-tests were applied to test continuous variables and chi-square for categorical data. Pearson product-moment correlations were computed to examine the strengths of the associations among variables. Building upon the classical theory of [@ref5]), mediational analyses based on nonparametric bootstrapping for standard errors, including bias-corrected and accelerated (BCa) 95% confidence intervals (CI) were performed ([@ref62], [@ref63]) to examine whether anhedonia and DDT-*k* mediate the associations between BAS and PAL SRA/non-SRA cross-product in both separate samples (see [Fig. 1](#f1){ref-type="fig"}). Anhedonia and DDT were included in the tested model together. Such analyses have been recommended for relatively small samples, do not require distributional assumptions and have a quite low risk of inducing a Type I error. The indirect macro was employed to build a multiple mediational model. The bootstrap estimates were based on 5000 resamples (*z* = 5000). All *P*-values were two-sided and considered statistically significant at *P* \< 0.05. All statistical analyses were performed using SPSS 20.0.

![Path model for multiple mediation analysis. In the upper panel of this figure, the patch coefficient denoted C represents the total relationship between BAS sensitivity and PAL substance/non-SRA engagement (SRA/non-SRA), not controlling for DDT-*k* values and SHAPS anhedonia. The lower panel of this figure illustrates the hypothesized causal model. The path denoted A represents the conditional effect of BAS impulsivity on DDT-*k* values/SHAPS anhedonia; the path denoted B represents the unconditional effect of DDT*-k* values/SHAPS anhedonia on PAL SRA/non-SRA. The strength of the mediated connection is found by multiplying A × B. The path denoted C′ represents the direct association between BAS sensitivity and PAL SRA/non-SRA, controlled for the mediated paths involving DDT-*k* values/SHAPS anhedonia.](agz105f1){#f1}

Results {#sec11}
=======

Group effects {#sec12}
-------------

Patients reported statistically significantly higher scores than controls in terms of all three PAL SRA scores: frequency \[*t* (58.94) = −6.36, *P* \< 0.001\], enjoyability \[*t* (72) = −5.20, *P* \< 0.001\] and PAL cross-product. Furthermore, similar findings were obtained regarding PAL RR (see [Table 2](#TB2){ref-type="table"} for an overview). Moreover, patients scored significantly higher than controls on DDT-*k* and SHAPS (see [Fig. 2](#f2){ref-type="fig"}). No statistically significant group differences were found on BAS and all three PAL non-SRA scores: frequency, enjoyability, and cross-product.

###### 

Group differences

                     Patients   (*N =* 37)   Controls   (*N =* 37)           *t* (*df*)
  ----------------- ---------- ------------ ---------- ------------ -----------------------------
                        M           SD          M           SD      
  BAS sensitivity     37.05        6.87       39.38        6.61            *t* (72) = 1.48
  DDT *k*-value       −1.38        1.35       −2.54        0.94      *t* (58.69) = −4.15^\*\*\*^
  SHAPS anhedonia     28.68        8.76       22.32        7.85       *t* (58.94) = −3.29^\*\*^
  PAL SRA             730.62      419.84      291.62      209.12      *t* (72) = −5.69^\*\*\*^
  PAL non-SRA         907.11      460.07      769.34      222.48         *t* (51.96) = −1.64
  PAL RR               0.45        0.12        0.26        0.11       *t* (72) = −6.75^\*\*\*^

*Note*: Figures are means and standard deviations. PALSRA/non-SRA indices represent PAL cross-product scores.

PAL RR is reinforcement ratio. Significant group differences indicated by ^\*^*P* \< 0.05,^\*\*^*P* \< 0.01,^\*\*\*^*P* \< 0.001.

![Mean discounting function by patients and controls. The curves for both patients and controls are indifference points that represent points at which participants prefer a small immediate value instead of a higher delayed value for a given delay period as a function of delay. Group differences were statistically significant \[*F* (1, 72) = 17.00, *P* \< 0.001, partial eta squared = 0.19\]. Range *k* values patient sample = 9.16, range *k* values control sample = 2.22.](agz105f2){#f2}

Pearson product-moment correlations: subgroup analyses {#sec13}
------------------------------------------------------

In both patients and controls, BAS was positively associated with PAL non-SRA cross-product (see [Table 3](#TB3){ref-type="table"}). Albeit somewhat weaker, BAS was also positively related to PAL SRA cross-product in the patient group. Only low and non-meaningful correlates emerged between DDT-*k* and PAL scores in both groups. Moreover, the correlation between SHAPS and PAL SRA cross-product and PAL RR did not reach statistical significance in both samples. The link between SHAPS and PAL non-SRA was negative and statistically significant in both groups. BAS was negatively correlated with DDT-*k* in the control group and with SHAPS in both patients and controls. DDT-*k* was positively correlated to SHAPS in the patient group only.

###### 

Univariate strength of correlations between measures

                              1          2         3                 4                   5               6
  --------------------- ------------- ------- ----------- ----------------------- ---------------- -------------
  1\. BAS sensitivity        --        −0.30   −0.45^\*^         0.40^\*^          **0.53^\*\*^**      −0.13
  2\. DDT *k*-value       −0.34^\*^     --     0.39^\*^            0.05                −0.04           0.06
  3\. SHAPS anhedonia    −0.45^\*\*^   0.08       --               −0.01            −0.43^\*\*^     0.44^\*\*^
  4\. PAL SRA               0.09       −0.07     0.13               --             **0.53^\*\*^**   0.48^\*\*^
  5\. PAL non-SRA        0.47^\*\*^    0.21    −0.35^\*^           0.28                  --         −0.44^\*\*^
  6\. PAL RR                −0.20      −0.07   0.36^\*^    [**0.80^\*\*^**]{.ul}       −0.28            --

*Note*: Figures are Pearson product-moment correlations. Strong correlations (\>0.50; [@ref12], [@ref13]) are presented in bold, very strong correlations (\>0.70) are also underscored. The correlational values above the diagonal mirror represent the patient sample and those below the diagonal represent the control group. PALSRA/non-SRA indices represent PAL cross-product scores. PAL RR is reinforcement ratio. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001.

Mediational model: subgroup analyses {#sec14}
------------------------------------

[Table 4](#TB4){ref-type="table"} displays the mediational indices of both subgroups. In the patient sample, statistically significant total effects were shown between BAS and PAL SRA/non-SRA cross-product, except for PAL RR (C = −0.3, *P* \> 0.05). Indirect effects through DDT-*k* and SHAPS between BAS and PAL SRA/non-SRA cross-product scores did not reach statistical significance. In the control sample, a statistically significant total effect emerged between BAS and PAL non-SRA cross-product. The DDT-*k* partially mediated this relationship (A1 × B1 = −4.45, BCa95% CI = −12.90 to −0.42) and acted as a suppressor variable, since the value representing the magnitude of the relationship between BAS and PAL non-SRA increased while DDT-*k* was included. Subsequently, additional analyses were conducted with only single mediators showing that the increase of the direct effect with respect to the total effect was caused by DDT-*k* (C = 14.83, *P* \< 0.01; C′ = 19.47′ *P* \< 0.001) and not by SHAPS (C = 15.82, *P* \< 0.01; C′ = 13.16′ *P* \< 0.05).

###### 

Results of mediation analysis for BAS sensitivity as predictor of PAL SRA/non-SRA with paths to represent mediation by DDT *k*-values and SHAPS anhedonia

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   Sample     Total\                   Direct effect BAS sensitivity   Mediation by\   CI          Mediation by SHAPS anhedonia   CI                                                                                
                              effect BAS sensitivity                                   DDT k-values                                                                                                                                 
  ---------------- ---------- ------------------------ ------------------------------- --------------- ----------- ------------------------------ ------------ ----------- ------------- ---------- ------- ----------- ----------- ------------
  PAL SRA          Controls   −0.94                    1.07                            −0.05^\*^       −15.10      0.75                           −1.60        7.64        −0.60^\*\*^   4.59       −2.77   −10.07      1.07        0.03

                   Patients   22.68^\*\*^              29.77^\*\*^                     −0.06           37.63       −2.19                          −14.20       2.81        −0.60^\*\*^   8.15       −4.90   −13.05      5.41        0.26^\*^

  PAL non-SRA      Controls   14.83^\*\*^              16.93^\*\*^                     −0.05^\*^       89.54^\*^   −4.45                          **−12.90**   **−0.42**   −0.60^\*\*^   −3.89      2.35    −3.15       8.86        0.35^\*\*^

                   Patients   35.80^\*\*^              31.43^\*\*^                     −0.06           72.61       −4.22                          −18.06       1.36        −0.60^\*\*^   −14.27     8.59    −0.22       28.04       0.36^\*\*^

  PAL RR (x 100)   Controls   −0.54                    −0.40                           −0.05^\*^       −2.03       0.1                            −0.04        0.47        −0.60^\*\*^   0.39       −0.23   −0.56       0.01        0.19

                   Patients   −0.28                    0.07                            −0.06           −1.14       0.07                           −0.07        0.41        −0.60^\*\*^   0.68^\*^   −0.41   **−0.94**   **−0.12**   0.22
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*: Displayed are the outcomes of the independent samples. PAL SRA/non-SRA indices represent cross-product scores. PAL RR is reinforcement ratio. Indices are unstandardized. The PAL RR was multiplied by factor 100 to obtain a percentage score. The confidence intervals not containing a zero are bold-font marked. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001.

Discussion {#sec15}
==========

The aim of this study was to investigate the relationship between BAS and PAL SRA/non-SRA in patients with AUD and healthy controls. DDT-*k* and SHAPS were included in correlational analyses, by using a mediational design, to examine their impact on this relationship. The main hypothesis of the current study assumed that both delay discounting and anhedonia would show a negative influence on the BAS-non-SRAs relationship, while delay discounting and anhedonia would show a positive impact on the BAS-SRA relationship. It emerged that patients with a higher level of BAS reward sensitivity engaged more in PAL non-SRA. Furthermore, individuals with higher DDT-*k* engaged in more PAL SRA, while higher levels of anhedonia were inversely related to PAL non-SRA. Moreover, anhedonic patients tended to prefer a small immediate reward above large delayed rewards. Besides, it was confirmed that BAS predicted PAL non-SRA. In the control sample, DDT-*k* partially influenced the relationship between BAS and PAL non-SRA cross-product score. These findings suggest that discount rates play a role in the relationship between reward sensitivity and engagement in non-SRAs in controls and partially confirm our hypothesis with respect to delay discounting. Anhedonia was not found to influence the BAS PAL-SRA/PAL non-SRA relationship in this present study.

Previous studies have shown a lower level of activity engagement among patients with AUDs compared to healthy individuals ([@ref22]; [@ref72]). However, in the current study, no statistically significant differences were found between both groups in terms of PAL non-SRA. This dissimilarity could be related to the double scoring format that was used to measure separate PAL SRA and non-SRA levels, as opposed to studies that used a single scoring format. This possible source of bias regarding activity measures was no longer observed when RR scores were calculated. As mentioned previously, promoting healthy activity engagement has become a crucial aspect of behavioral addiction treatment to compete with SRAs ([@ref71]; [@ref53]; [@ref52]; [@ref18]). However, it emerged that roughly similar rates of PAL non-SRA activity frequency and enjoyability scores were obtained in both groups. Analog to students, alcohol use among patients might also be associated with aspects of (social) benefits and partner intimacy, and may act as an important social facilitator (e.g. [@ref21]; [@ref82]).

The present study corroborates with previous findings in terms of discount rates ([@ref57]) and anhedonia ([@ref37]; [@ref27]) in AUD patients. That is, discount rates were positively linked with SRAs ([@ref57]), while previous work demonstrated that anhedonia was negatively associated with substance-free activities ([@ref47]). However, our data did not support this latter association.

This current study has several methodological strengths. The matched-control design ruled out possible confounding effects of demographical variables (gender, age, nationality and education) on the results of this study. The missing data were managed by the use of the EM, which was applied separately for each scale ([@ref75]). Moreover, to estimate direct and indirect effects of BAS sensitivity on different PAL activity scores with DDT discount rates and SHAPS anhedonia, the methodology of [@ref62], [@ref63]) was used, advocated to overcome possible violations of the assumption of a normal distribution of the scales.

Nevertheless, there are also some limitations that have to be addressed. First, the study sample was relatively small. As such, therefore it was not desirable to correct for a Type 1 error and add covariates such as gender or age. Second, because of cross-sectional design of the present study with relatively small sample size, it was not appropriate to test the bidirectionality of the associations or to draw conclusions with respect to causality. Hence, it cannot be ruled out that alternative explanations may be viable too ([@ref50]). Third, although a case-matched design has been used, the sample in both groups consisted mainly of males, which has to be taken into account when generalizing the current findings to other populations or diagnostic groups. It must be noted that patients were admitted to an inpatient alcohol-detoxification unit for at least one week. Such a time-frame is frequently sufficient to complete the medically assisted withdrawal. Although even the data collection took place after a mean number of 23 days, we cannot exactly rule out the impact of (protracted) withdrawal symptoms in influencing the scores on the assigned measures. A possible influence of withdrawal symptoms on the measurement of anhedonia in the current study cannot be excluded since it has been substantiated that a possible decrease of dopaminergic state due to long-term substance use has to be taken into account while using the findings regarding reward sensitivity within the clinical practice ([@ref69]; [@ref85], [@ref86]). Moreover, this study positioned the delay discounting as a consequence of long-term substance use ([@ref80]; [@ref14]). However, it should be noted that delay discounting may act as a risk factor for substance use and may predict the likelihood to recover from substance use as well ([@ref70]). Yet both hypothetical aspects or even a reciprocal effect seems plausible, though remain inconclusive due to the small sample size and cross-sectional design of this study.

The results suggest that those who report higher sensitivity to rewards is more inclined to engage in prosocial healthy activities. Only in the control sample, we found a result that discounting delayed values suppresses this association, but on the other hand, stimulates the engagement in non-SRAs as well. The control sample was characterized with general low alcohol consumption (AUDIT \<  8) and therefore the level of SRAs was low as well, especially compared to patients. Despite the typical negative connotation surrounding 'delay discounting' it seems that it may have a positive influence on non-substance-related pleasant activity engagement. Owing to the positive association between reward sensitivity and extraversion that has been substantiated in previous research ([@ref26]), this study emphasizes the importance to assess information about patients' individual differences in terms of appetitive motivation or reward sensitivity related to prosocial activity engagement that could support therapists to promote a sufficient level of adequate reinforcement derived by alternative and more healthy behaviors ([@ref73]). To assist this formidable task, prescribed incentives can be employed contingent on a 'successive approximation' toward a desired healthy activity engagement to enhance the short-term reinforcement magnitude.

Conclusion {#sec16}
==========

Reward sensitivity levels appear to be strongly linked to engagement in non-SRAs in both patients and controls. In addition, we found that delay discounting affects the relationship between reward sensitivity and engagement in non-SRAs only in the control group. Future studies should include larger sample sizes with an equal distribution of gender. This would increase the validity and generalization of the current findings.
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